Senolytic supplements and drugs: what actually has human data
Senolytics are supposed to clear out old, damaged cells that build up as we age. A couple of prescription-drug combinations have small human studies behind them; the popular over-the-counter supplement version (fisetin) mostly doesn't.
Senolytics are drugs or compounds designed to selectively clear senescent ("zombie") cells that accumulate with age. Dasatinib plus quercetin (D+Q) is the combination with the most human data — small trials in idiopathic pulmonary fibrosis and diabetic kidney disease showed it reduces senescent-cell markers and improved physical function in one trial. Fisetin, the senolytic most widely sold as a standalone supplement, has no published, adequately powered, placebo-controlled human trial showing a clinical benefit at consumer doses — its basic pharmacokinetics in humans are still being characterised. No senolytic has improved a hard clinical outcome in an adequately powered randomised trial.
- D+Q reduced senescent-cell burden (p16+ and p21+ cells, SASP inflammatory markers) in a nine-person diabetic kidney disease pilot trial — a mechanism result, not a proven clinical outcome, and the sample size is too small to generalise from.
- A separate small D+Q trial in idiopathic pulmonary fibrosis reported improved physical function measures, one of the first human signals that clearing senescent cells might translate to a functional benefit.
- Fisetin, sold widely as an over-the-counter senolytic supplement, lacks any adequately powered, placebo-controlled human trial demonstrating clinical benefit — its pharmacokinetics at the doses typically sold are not well characterised.
- As of 2026, roughly two dozen senolytic-related studies are registered on ClinicalTrials.gov, spanning conditions from Alzheimer's risk to frailty — most are small, early-phase, and not yet reporting results.
- "Reduces markers of senescence" and "improves a disease outcome" are different claims. Every senolytic sold today has, at best, evidence for the first — none has adequately powered evidence for the second.
What each senolytic actually has behind it
Senolytic compounds, ranked by human evidence quality
| Compound | Form | Strongest human evidence | What it does NOT show |
|---|---|---|---|
| Dasatinib + Quercetin (D+Q) | Prescription drug + supplement, combined | Reduced senescent-cell markers in a 9-person diabetic kidney disease pilot; improved physical function measures in a small idiopathic pulmonary fibrosis trial | No adequately powered trial has shown it improves a hard clinical endpoint (mortality, major organ outcome) in any population |
| Fisetin | Over-the-counter supplement | Strong preclinical (mouse) senolytic activity; human pharmacokinetics still being characterised as of 2026 | No published, adequately powered, placebo-controlled human trial showing clinical benefit at the doses commonly sold |
| Quercetin (alone) | Over-the-counter supplement | Long history of use as a general antioxidant supplement; senolytic activity mainly studied in combination with dasatinib, not alone | No standalone senolytic trial evidence — its role in trials is always paired with dasatinib |
What the actual trials measured
The most-cited human senolytics study gave nine adults with diabetic kidney disease a three-day oral course of dasatinib (100 mg) plus quercetin (1000 mg), then measured senescent-cell markers 11 days later. Adipose and epidermal senescent-cell abundance fell, along with p16+ and p21+ cell counts and circulating inflammatory SASP factors including IL-1α, IL-6 and MMPs. That is a genuine biological signal — the drugs did what they were designed to do at the cellular level — but with nine participants and no placebo control on the biomarker endpoints, it cannot tell you whether clearing those cells changed anyone's actual kidney disease outcome.
A separate small trial of D+Q in idiopathic pulmonary fibrosis (a scarring lung disease) reported improvements in physical function measures, one of the first signals connecting senolytic treatment to something closer to how a patient actually feels or functions, rather than a lab marker alone.
Frequently asked questions
Does fisetin actually work as a senolytic in humans?
It has strong senolytic activity in mouse and cell-culture studies, but there is no published, adequately powered, placebo-controlled human trial showing a clinical benefit from oral fisetin supplementation at the doses typically sold. Its basic human pharmacokinetics — how much of an oral dose is actually absorbed and reaches relevant tissue — are still being characterised as of 2026, which makes it hard to know if consumer doses even approximate what worked in animal studies.
Is dasatinib plus quercetin (D+Q) safe to take for senolytic purposes?
Dasatinib is a prescription cancer chemotherapy drug (a tyrosine kinase inhibitor) with known, sometimes serious side effects at cancer-treatment doses, and it is not approved for senolytic or anti-aging use at any dose. The small trials that used it for senolytic purposes did so under medical supervision at specific, lower short-course doses for a specific patient population — this is not the same as an unsupervised, ongoing off-label senolytic protocol, which carries real risks that haven't been characterised in a healthy population.
How many senolytic trials are currently running?
As of 2026, roughly two dozen senolytic-related studies are registered on ClinicalTrials.gov, spanning conditions including diabetic kidney disease, pulmonary fibrosis, frailty, osteoarthritis and Alzheimer's-risk populations. Most are early-phase and have not yet reported results — the evidence base is expected to grow substantially over the next several years, but is thin today.
Should I take a senolytic supplement now, or wait for more evidence?
That's a personal risk decision this site doesn't make for anyone — but the facts to weigh are: over-the-counter senolytics like fisetin currently have no adequately powered human trial evidence of clinical benefit, prescription-based D+Q protocols have only small, short, biomarker-focused human data, and none of these compounds is approved for this use by any regulator. If you're already taking one, that's information for a conversation with your own physician, not a reason for panic — but "human data exists" and "proven to work" are different claims, and most of what's marketed today is the former dressed as the latter.
Keep reading
- Anti-Aging Pharma
How senolytics compare to the other drug classes being marketed for aging.
- Biological age tests
The other number the longevity industry sells, graded the same way.
More in Supplements
- Which science-backed supplements can safely extend life?
Supplements ranked on both human evidence and safety for genuine life-extension claims: vitamin D correction, omega-3 in specific groups, creatine, fibre, and a short honest list of what does not qualify — with why almost nothing marketed as a longevity supplement meets both bars at once.
- Best anti aging supplements to extend life naturally.
Anti-aging supplements ranked on human evidence for extending life or healthspan naturally: correcting vitamin D and B12 deficiency, omega-3 in specific groups, creatine, collagen for skin, and a clear-eyed look at NMN, resveratrol and other popular 'natural' anti-aging supplements with weak human evidence.
- Complete supplement stack designed to extend lifespan effectively.
A supplement stack built strictly from items with genuine human evidence for extending lifespan or supporting healthy ageing: correcting deficiencies, omega-3 in specific groups, creatine, fibre, and protein — with why a shorter, evidence-based stack is more effective than a longer, comprehensive-sounding one.
- Best longevity supplements for cellular health and repair
Ranked on human trials only: which supplements have actually moved a cellular-repair marker in people — mitochondria, autophagy, NAD⁺, oxidative stress — and which are still mouse data.
- What are the best science-backed longevity supplements?
'Science-backed' is the most abused phrase in supplements. Here is what it should mean, the five-question test, and the short list that actually passes on human trials.
- What are the best clinically proven longevity supplements?
Proven for what, in whom, at what dose? Every longevity supplement with a completed randomised trial on a clinical endpoint — and the exact claim each trial supports.